Sun, Feb 1, 2015, 6:20 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • boeblingenbud boeblingenbud Aug 28, 2013 1:47 PM Flag

    Eli Lilly Enters Targeted Anti-body payload with IMGN

    Hey good news is here. IMGN may get up to 200.5 mil with Eli - Lilly. HOT OF THE PRESS.

    Take that OPPY and find fault.

    BOE

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Seeking Alpha had an alert...LLY buying the TAP technology for 200 million plus future royalties.

    • Nice, good POSITIVE stuff.

      On August 26, 2013, ImmunoGen, Inc. (Nadaq: IMGN) entered into a license agreement with Eli Lilly and Company (NYSE: LLY) granting Lilly rights to use our maytansinoid-based Targeted Antibody Payload (TAP) technology to develop and commercialize products directed to a specific antigen target on an exclusive basis. This license was granted pursuant to the terms of an existing Multi-Target Agreement entered into by the Company and Lilly in 2011.

      In accordance with the terms of the Multi-Target Agreement, execution of the license agreement entitles us to receive development, regulatory and sales milestone payments potentially totaling $200.5 million, as well as royalties on the commercial sales of any resultant products.

    • No press release, just a filing, nice IR work. Maybe it's coming later after they confer with LLY. Must be for the Erbitux molecule no? Super Erbitux sounds good.

 
IMGN
7.63+1.4300(+23.06%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.